Vaccination Of Goats Research Articles

Evaluation of mucoadhesive property and the effect of Boswellia carteri gum on intranasal vaccination against small ruminant morbillivirus infection (PPR)

ABSTRACTA study was conducted to evaluate mucoadhesive property and immunomodulatory effect of phytogenic gums from Boswellia frereana, Boswellia carteri andCommiphora myrrha on intranasal Peste des petits ruminants (PPR) vaccination in goats and sheep in an ex-vivo and in-vivo situations. Plant gums were purified, dried and compressed into 500gm tablets. Modified shear stress measurement technique was used on freshly excised trachea and intestine tissues of goat to measure peak adhesion time. Forty eight animals (24 goats and 24 sheep) were divided into eight groups (of 3 goats and 3 sheep) and immunized intranasally with gum-vaccine combinations in two ratios (1:1, 1:2). Antibody against PPR virus was measured on day 14, 28, 42 and 56 post vaccination using H-based PPR bELISA. The peak adhesion time of the different gums was transient. PPR virus antibodies were detected in all immunized goats and sheep but not in unvaccinated control. The best percentage inhibition was recorded for Boswellia carteri-vaccine combination group at a ratio of 1:1. Administration of Boswellia carteri-PPR vaccine combination through intranasal or subcutaneous route, elicited similar antibody titre, implying that the intranasal route may be used as a non-invasive alternative delivery in PPR vaccination of small ruminants.

Protective effect of intranasal peste des petits ruminants virus and bacterin vaccinations: Clinical, hematological, serological, and serum oxidative stress changes in challenged goats.

Background and Aim:The current vaccination for peste des petits ruminants virus (PPRV) is stalled by myriad challenges and continuous endemicity of pneumonia due to fulminant bacterial complication in goats. The present study evaluated the protective effect of intranasal PPRV linage 1 and bacterine vaccinations.Materials and Methods:Twelve West African Dwarf (WAD) goats aged 6 months were randomly grouped and vaccinated within 2 weeks using a combination of PPRV lineage 1 vaccine (Nig/75), and bacterin from Mannheimia haemolytica (Mh) or Pasteurella multocida intranasally. The goats were observed for 3 weeks post-vaccination before comingled with a known infected WAD goat with apparent clinical signs of peste des petits ruminants and further observed clinically for 5 weeks post-infection (PI). Blood samples were taken for hematology while sera were assayed for antioxidants (glutathione peroxidase, glutathione transferase, and superoxide dismutase) activities and pro-oxidants (malondialdehyde content, reduced glutathione, hydrogen peroxide generation, and myeloperoxidase) using spectrophotometric methods. Data were subjected to parametric statistics at α=0.05 using GraphPad Prism version 21.Results:Clinically, there were pyrexia, oculonasal discharge, diarrhea, anemia, leukopenia, and increased pro-oxidants in the unvaccinated goats, while moderate neutrophilia and leukocytosis were observed in PPRV and bacterin vaccinated goats. Two unvaccinated goats were weak and euthanized at 13 and 28 days PI. The goats vaccinated with PPRV and Mh showed better response clinically and biochemically.Conclusion:The mucosal vaccination of goats with PPRV vaccine and bacterine will protect against exposure and culminate in the development of protective mucosal, humoral, and cell-mediated immune responses. This vaccination strategy will provide framework needed in the prevention and control of endemic caprine pneumonia in Nigeria.

Protective Effect of Intranasal Peste des Petits Ruminants Virus and Bacterine Vaccinations: Clinical, Haematological, Serological and Serum Oxidative Stress Changes in Challenged Goats

The current vaccination for Peste des Petits ruminants PPR is stalled by myriad challenges and continuous endemicity of pneumonia due to fulminant bacteria complication in goats. The present study evaluated the protective effect of intranasal PPR virus linage 1 and bacterine vaccinations. Twelve West African Dwarf goats aged 6 months were randomly grouped and vaccinated within two weeks using combination of PPRV linage 1 vaccine (Nig/75), and bacterine from Mannheimia haemolytica (Mh) or Pasteurella. multocida (Pm) intranasally as A (vaccinated with PPRV & Mh), B (vaccinated with PPRV & Pm), and C (unvaccinated). All the goats were observed for three weeks post vaccination before comingling with a known infected WAD goat showing clinical signs of PPR and further observed clinically for five weeks (35days) post infection. Blood samples were taken for haematology and while sera were assayed for antioxidants (Glutathione Peroxidase GPx, Glutathione Transferase GST, Superoxide Dismutase SOD) activities and prooxidants (Malondialdehyde content, Reduced Glutathione GSH, Hydrogen peroxide H2O2 generation, Myeloperoxidase) using spectrophotometric methods. Data was subjected to parametric statistics at α=0.05 using Graph pad prism version 21. Clinically, there was pyrexia, mucopurulent oculo‐nasal discharge, diarrhoea, anaemia, leucopaenia and increased prooxidants in the unvaccinated goats (C), while moderate neutrophilia and leucocytosis were observed in PPRV and bacterine vaccinated goats. Two unvaccinated goats died at 13 and 28 days post infection. The goats vaccinated with PPRV and Mh showed better response. In conclusion, mucosal vaccination of goats with PPRV vaccine and bacterine will protect against exposure and culminate in the development of protective mucosal, humoral and cell‐mediated immune responses. This vaccination strategy will provide protection needed in the prevention and control of endemic caprine pneumonia in Nigeria.This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal.

Effect of Vitamin E Supplementation on Humoral Immunity Following the Administration of Enterotoxaemia Vaccine in Goats

Effect of Vitamin E Supplementation on Humoral Immunity Following the Administration of Enterotoxaemia Vaccine in Goats

ANTIGENIC AND PROTECTIVE PROPERTIES OF EXPERIMENTAL ASSOCIATED VIRUS VACCINE AGAINST SHEEP POX AND GOAT POX

Studies have been carried on antigenic and protective activity of the experimental associated vaccine containing, in the field vaccination dose, antigens of the attenuated ARRIAH strain of the sheep pox virus and ARRIAH 2003 strain of the goat pox virus in the ratio of 4.24 and 4.24 lg TCD50/cm3, 4.18 and 4.37 lg TCD50/cm3and 4.37 and 4.18 lg TCD50/cm3respectively, as well as monovalent vaccines with the infectious activity of these strains with a titer of 4.5 lg TCD50/cm3. Administration of the associated virus vaccine did not adversely affect the physiological state of the animals and was accompanied by the formation of viral neutralizing antibodies in protective titres that did not differ from antibody titers in the blood of sheep and goats during monovalent immunization. High levels of virus neutralizing antibodies in the range of (3.50 ± 0.50)–(4.05 ± 0.22) and (3.58 ± 0.08)–(4.00 ± 0.29) log2respectively were determined in the blood serum of all sheep and goats vaccinated with associated vaccines. The antigenic activity of the associated vaccines for goats and sheep is almost identical. There were no negative effects on the antigenic activity of different ratios of attenuated strains of the sheep pox and goat pox virus in the inoculation dose. All sheep immunized with the monovalent vaccine against sheep and goat pox and associated virus vaccines, resisted the disease when challenged with a virulent sheep pox virus “Afghanistan” strain. Three sheep vaccinated with a monovalent vaccine against goat pox demonstrated a large local reaction, one sheep was diagnosed with generalized form of sheep pox.

Efficacy of parenteral vaccination against tuberculosis with heat-inactivated Mycobacterium bovis in experimentally challenged goats.

Tuberculosis (TB) in animals is a re-emerging disease with a wide range of hosts that causes large economic losses in livestock. Goats are particularly susceptible to TB and, in endemic areas, vaccination may be a valuable measure to control the disease. The main aim of this study was to evaluate the efficacy of parenteral vaccination of goats with a heat-inactivated Mycobacterium bovis (HIMB) vaccine, and compare it to M. bovis Bacille Calmette–Guérin (BCG) vaccine. Twenty-four goat kids were divided in 3 groups as following: HIMB vaccinated group (n = 8), BCG vaccinated group (n = 8) and unvaccinated group (n = 8). Afterwards, goats were experimentally challenged with Mycobacterium caprae by the endobronchial route. Antigen specific interferon-γ release assays and serology were performed after vaccination and challenge. Pathological and bacteriological parameters were evaluated after necropsy at 9 weeks post-challenge (p.c.). HIMB vaccine showed similar levels of protection to BCG in terms of volume reduction of thoracic TB lesions, presence of extra-pulmonary lesions, as well as a slight reduction of bacterial load in pulmonary lymph nodes. Moreover, HIMB vaccine did not induce interferences on the interferon-γ release assay based on reagents previously developed to differentiate infected from BCG vaccinated individuals. The results indicate that HIMB is a suitable vaccine candidate for further larger-scale trials under field conditions in goats.

Immunocastration of goats using anti-gonadotrophin releasing hormone vaccine

The aim of this study was to evaluate the immuno-sterilizing action of anti-gonadotrophin-releasing hormone (anti-GnRH) vaccine in goats. Eighteen male goats were randomly distributed to receive three treatments: T1 (control) - whole animals, and T2 and T3 - application of 0.5 and 1.0 mL of anti-GnRH vaccine, respectively, with six replicates and one goat per experimental unit. Vaccine was administered at 8 months of age and 30 days after the first immunization. Testicular biometry was evaluated monthly, along with seminal collections, for the physical and morphological evaluation of semen. At the time of slaughter, the testicle were collected, and fragments were measured and removed for histological evaluation. The data were evaluated for normality by the Shapiro-Wilk test, followed by appropriate statistical tests for each variable. A reduction in width and length of the right and left testicles was observed and, consequently, the scrotal circumference of the immunized animals reduced after the second vaccine application (P < 0.05). Thirty-days after the first vaccine application, there was a negative effect on seminal production and quality; and 60 days after the second application, a pronounced reduction was observed in all seminal parameters in the vaccinated animals, including azoospermia (83.33% of animals; P < 0.05). Vaccine application reduced testicular weight, seminiferous tubule diameter, and gonadosomatic and tubulosomatic index (P < 0.05), but did not influence the proportion of testicular parenchyma components (P > 0.05). Two applications of the anti-GnRH conjugate are effective for the immunological castration of goats, and the 0.5 mL dose is recommended for use in crossbred goats.

Expression of cytokines following vaccination of goats with a recombinant capripoxvirus vaccine expressing Rift Valley fever virus proteins

The mosquito-borne Rift Valley fever virus (RVFV) causes severe diseases in domesticated animals including cattle, sheep, camels and goats. Capripoxviruses (CPV) are suitable vectors for multivalent vaccine development. A recombinant rKS1-based CPV expressing the gene encoding the viral glycoprotein Gn of RVFV has been shown to induce protection in mice and sheep. The aim of this study was to evaluate the immunogenicity induced by this candidate vaccine in goats, and the level of cytokines produced by RVFV-specific Th1 and Th2 lymphocytes. The results of this study suggest that Th2 mediates immunity mainly through the significant production of IL4, which, coupled with a decrease in IFN-γ, may be involved in the replication of the capripoxvirus expressing the GN of RVFV. CD4+ cells may play the role of helper cells in B cell responses and neutralizing antibody production in the anti-CPV humoral response, leading to strong immunity against RVFV.

Concurrent vaccination of goats with foot and mouth disease (FMD) and peste des petits ruminants (PPR) booster vaccines.

Foot and mouth disease (FMD) remains subclinical and self-limiting in small ruminants, but risk of spread of infection to susceptible cohorts is of great epidemiological significance; therefore, small ruminants must be included in vaccination campaigns in FMD endemic regions. Three groups of goats already immunized against peste des petits ruminants (PPR) were vaccinated with FMD and PPR vaccines alone or concurrently. The specific antibody response against three FMD virus strains and PPR virus were evaluated by competitive enzyme-linked immunosorbent assay (cELISA). Goats concurrently vaccinated with PPR+FMD vaccines had significantly (p<0.05) higher antibody titers to two serotypes of FMD virus at 28, 45, and 60days post-immunization compared to goats vaccinated with FMD vaccine alone, while goats vaccinated with PPR vaccines alone or PPR+FMD vaccines concurrently showed similar antibody kinetics against PPR virus up till 60days post-vaccination. Overall, antibody kinetic curves for all three tested strains of FMD virus and PPR virus were similar in vaccinated groups during the course of experiment.

Use of the mice passive protection test to evaluate the humoral response in goats vaccinated with Sterne 34F2 live spore vaccine

The Sterne live spore vaccine (34F2) is the most widely used veterinary vaccine against anthrax in animals. Antibody responses to several antigens of Bacillus anthracis have been described with a large focus on those against protective antigen (PA). The focus of this study was to evaluate the protective humoral immune response induced by the live spore anthrax vaccine in goats. Boer goats vaccinated twice (week 0 and week 12) with the Sterne live spore vaccine and naive goats were used to monitor the anti-PA and toxin neutralizing antibodies at week 4 and week 17 (after the second vaccine dose) post vaccination. A/J mice were passively immunized with different dilutions of sera from immune and naive goats and then challenged with spores of B. anthracis strain 34F2 to determine the protective capacity of the goat sera. The goat anti-PA ELISA titres indicated significant sero-conversion at week 17 after the second doses of vaccine (p = 0.009). Mice receiving undiluted sera from goats given two doses of vaccine (twice immunized) showed the highest protection (86%) with only 20% of mice receiving 1:1000 diluted sera surviving lethal challenge. The in vitro toxin neutralization assay (TNA) titres correlated to protection of passively immunized A/J mice against lethal infection with the vaccine strain Sterne 34F2 spores using immune goat sera up to a 1:10 dilution (rs ≥ 0.522, p = 0.046). This study suggests that the passive mouse protection model could be potentially used to evaluate the protective immune response in livestock animals vaccinated with the current live vaccine and new vaccines.

Field evaluation of the efficacy of Mycobacterium bovis BCG vaccine against tuberculosis in goats

BackgroundControl of animal tuberculosis (TB) through vaccination has emerged as a long-term strategy to complement test and slaughter control strategy. A pilot trial under field conditions was conducted in a goat herd with high TB prevalence to assess the efficacy of the Mycobacterium bovis BCG vaccine.ResultsTwenty-three goat kids vaccinated with BCG and other 22 unvaccinated control kids were euthanized at 18 months post-vaccination. Gross pathological and histopathological examination of target tissues was performed for detection of tuberculous lesions and assessment of vaccine efficacy. Mycobacterial culture and DNA detection were used to confirm Mycobacterium caprae infection. Vaccination significantly reduced the number of animals with TB lesions compared to unvaccinated controls (35% and 77%, respectively; P < 0.01). This reduction was even higher if only extra-pulmonary infection was considered (17% and 68%, respectively; P < 0.001).ConclusionsThis trial demonstrates that BCG vaccination of goats can significantly reduce the TB lesion rates in high disease exposure conditions, indicating that vaccination could contribute to the control of TB in domestic goats.

Evaluation of antibody response to Goat Pox cell culture vaccine in goats in India

Goat Pox is an important contagious viral disease that causes serious economic loss in small ruminants. The disease causes high morbidity, mortality and trade restriction. Several outbreaks of the disease are reported in Africa and Europe. In India also, the disease has high economic significance. Present study was undertaken to estimate specific antibody response to Live Goat Pox Vaccine in goats. Thirty-five healthy goats were vaccinated with single dose and 10 goats were kept as control. Blood was collected at defined intervals and sera were separated. Virus neutralization test was performed to estimate neutralization index as marker of antibody levels in serum. The study revealed that vaccine could induce immunity against the disease within seven days of vaccination, and reached a peak at 21 days. The titre remained at protective level throughout the oneyear study. Further study can be done to estimate the total duration of immunity through extended study, and the response to challenge with virus.Bangl. vet. 2016. Vol. 33, No. 1, 23-27

Vaccination against Louping Ill Virus Protects Goats from Experimental Challenge with Spanish Goat Encephalitis Virus

Spanish goat encephalitis virus (SGEV) is a recently described member of the genus Flavivirus belonging to the tick-borne encephalitis group of viruses, and is closely related to louping ill virus (LIV). Naturally acquired disease in goats results in severe, acute encephalitis and 100% mortality. Eighteen goats were challenged subcutaneously with SGEV; nine were vaccinated previously against LIV and nine were not. None of the vaccinated goats showed any clinical signs of disease or histological lesions, but all of the non-vaccinated goats developed pyrexia and 5/9 developed neurological clinical signs, primarily tremors in the neck and ataxia. All non-vaccinated animals developed histological lesions restricted to the central nervous system and consistent with a lymphocytic meningomyeloencephalitis. Vaccinated goats had significantly (P<0.003) greater concentrations of serum IgG and lower levels of IgM (P<0.0001) compared with unvaccinated animals. SGEV RNA levels were below detectable limits in the vaccinated goats throughout the experiment, but increased rapidly and were significantly (P<0.0001) greater 2-10 days post challenge in the non-vaccinated group. In conclusion, vaccination of goats against LIV confers highly effective protection against SGEV; this is probably mediated by IgG and prevents an increase in viral RNA load in serum such that vaccinated animals would not be an effective reservoir of the virus.

The unexpected discovery of Brucella abortus Buck 19 vaccine in goats from Ecuador underlines the importance of biosecurity measures.

Very few, mostly old, and only preliminary serological studies of brucellosis in goats exist in Ecuador. In order to assess the current epidemiological situation, we performed a cross-sectional serological study in the goat populations of Carchi (n = 160 animals), Pichincha (n = 224 animals), and Loja provinces (n = 2024 animals). Only two positive serological results (RB negative and SAT-EDTA ≥400IU/ml) were obtained in lactating goats from the same farm in Quito (Pichincha province). Additionally, milk was sampled from 220 animals in Pichincha province. The present study indicates a low apparent prevalence in Pichincha province and absence in Carchi and Loja provinces. A total of 25 positive milk ring tests (MRT) were obtained in Pichincha province yielding a prevalence of MRT of 11.16%. Subsequent culture was performed on the positive MRT samples. All results were negative, apart from a single sample, obtained from a serologically positive goat in Quito, that was positive for Brucella abortus strain 19 (B19). Several hypotheses are forwarded concerning this unexpected result. The most likely hypothesis is the possible accidental use of a needle, previously used for vaccination of cattle with the said vaccine, for the administration of drug treatment to the goat. This hypothesis underlines the necessity of biosecurity measures to prevent this type of accidents.

Efficacy of an Escherichia coli O157:H7 SRP Vaccine in Orally Challenged Goats and Strain Persistence Over Time.

Small ruminants have been implicated in outbreaks of Escherichia coli O157:H7 at livestock exhibitions throughout the United States. Additionally, goat meat or milk may serve as a reservoir for foodborne transmission of the organism. These associations highlight the public health importance of an effective strategy to reduce E. coli O157:H7 shedding in goats. We examined the efficacy of the SRP® vaccine in goats orally challenged with E. coli O157:H7. Mixed-breed goats (n = 14) were randomly allocated into vaccinated and unvaccinated treatments (n = 7 per treatment). Goats were housed with a vaccinated and unvaccinated animal in each pen. Feces were collected for 3 weeks, then at necropsy, gastrointestinal contents were collected to determine the concentration of E. coli O157:H7. Three isolates per positive sample were saved and evaluated by pulsed-field gel electrophoresis (PFGE) to assess strain persistence over time. The mean concentration of E. coli O157:H7 in the feces of goats was numerically reduced in the vaccinated treatment; however, it was not statistically significant. In addition, the total number of days goats were fecal positive for E. coli O157:H7 were not different between vaccinated and unvaccinated treatments. Pulsotypes of isolates revealed that goats initially shed two of the four challenge strains of E. coli O157:H7, after which there was a distinct shift to two different strains. Further work is needed to evaluate cost-effective intervention strategies that reliably reduce E. coli O157:H7 shedding in goats, particularly those that may reduce the risk of transmission at public events, including petting zoos and fairs.

Small ruminant farming and livelihood security in India: Present status and opportunities for enhancing farmers’ income

In the present paper, an attempt was made to explore the role of small ruminants rearing in livelihood and nutritional security of millions of landless, marginal and small farmers. Goat is the second largest livestock species after cattle in terms of number. Goat and sheep constitute 67.5% (135.17 million) and 32.5% (65.07 million) of total small ruminant's population (200 million) of the country respectively making 10 percent of the world small ruminant's population. Country stood second in goat and sheep population, first in goat milk production and second in goat meat and goat skin production in the world. It is an important source of income to farmers particularly in disadvantageous regions in the country where crop failure is the repeated phenomenon. Households cultivating less than 2.0 ha of land (marginal and small) are the main custodian and possess more than 76% goat and 70% of sheep population of the country, respectively. The demand for small ruminant is basically a derived demand necessitated by the demand for meat, milk, wool, hides, skins etc. High income elastic for livestock products, increasing domestic consumption due to increment in per capita income growth, variation in taste preference and urbanization are some of the driving factors of increasing demand for livestock products. The gap between demand and supply of goat meat/mutton will widen in future as meat demand may grow at faster rate than that of production. Goat milk which is also known as natural functional food contributes 4% to central milk pool (127 million tonnes).Goat based integrated livelihood models developed based on participatory research suggest that with 15 adult female goat and 25 chicks yield a net income of ₹ 82,727 per year. This model is suitable for landless and marginal group of farmers. Low cost goat technologies not only help in productivity enhancement but also improve the farmers’ price realization. Per goat per year return over variable cost was estimated to be 4800 to 5000. However, it was estimated to 4200–4500 per sheep per year. Small ruminant rearing at small scale may utilize family labour (women labour) efficiently and the problem of malnutrition in women and children may also solved. These returns may increase if farmer target festive season sale. Furthermore, through simple technological and marketing interventions- vaccination of goats, deworming, nutrition supplements, breeding with improved bucks and sale of kids at their commercial age may accrue economic gain of 5688 crore, net of cost at country level. To fetch these gains, efforts should be made to make goat farming more organized. Bridging knowledge gap, veterinary support and linking goat farmers with markets are the other key aspects for sustainable goat production and enhancing farmers’ income.

Vaccination of goats against Haemonchus contortus with the gut membrane proteins H11/H-gal-GP

Forty goats, aged from 2 to 5 months were subjected to two different immunization protocols with a vaccine containing Haemonchus contortus gut membrane proteins H11/H-gal-GP to evaluate protection against H. contortus on pre-contaminated pastures. Goats were allocated to four groups of ten, three of them received their first vaccination before turnout. One group (V4) was then vaccinated at 4-week-intervals whereas another two groups (V6 and V6SEP) were vaccinated at 6-week-intervals. A control group (CTRL) remained unvaccinated. In May, after the second vaccination, all goats were turned out on pastures which had been previously contaminated with H. contortus eggs by seeder sheep for a period of six weeks. Goats of groups V4, V6 and CTRL were grazed together, whereas V6SEP was kept separately at an identical stocking rate. Clinical (PCV, FAMACHA, body weight), parasitological (faecal egg count, FEC) and serological (antibody titres) parameters were measured fortnightly. All goats were stabled in October, drenched with levamisole and two weeks later infected with 5000 L3 of H. contortus and slaughtered four weeks later for determination of abomasal worm burdens. Group mean FEC peaked 42–56days after turnout. Significantly lower FEC were observed in V6SEP vs CTRL between D 28 and 70 (p<0.01). Mean egg output of all groups decreased substantially and fluctuated at low levels until the end of the grazing period (D 154). Goats responded to vaccination with increasing antibody titres peaking after every booster. Mean worm burdens deriving from experimental infections were reduced by 89, 65 and 47% in groups V4, V6 and V6SEP, respectively, compared with the controls. The difference was significant for V4 (p<0.01). Antibody titres measured 14days before slaughter did not correlate statistically with the worm burdens. It was concluded that the vaccination protocol did not result in sufficient protection on pasture, as antibody titres were still low at the time the goats were exposed to larval contamination on pasture after turnout.

Assessment of safety and interferon gamma responses of Mycobacterium bovis BCG vaccine in goat kids and milking goats

Vaccination of domestic animals has emerged as an alternative long-term strategy for the control of tuberculosis (TB). A trial under field conditions was conducted in a TB-free goat herd to assess the safety of the Mycobacterium bovis BCG vaccine. Eleven kids and 10 milking goats were vaccinated with BCG. Bacterial shedding and interferon gamma (IFN-γ) responses were monitored throughout the study. Comprehensive pathological examination and mycobacterial culture of target tissues were performed.BCG vaccine strain was only isolated from the draining lymph node of the injection site of a kid euthanized at week 8 post-vaccination. The remaining animals were euthanized at week 24. Six out of 20 showed small granulomas at the injection site. BCG shedding was not detected in either faeces or in milk throughout the study. All vaccinated kids showed BCG-induced IFN-γ responses at week 8 post-vaccination.BCG vaccination of goats showed no lack of biological safety for the animals, environment and public health, and local adverse reactions were negligible.

Immunomodulatory effect of levamisole on PPR vaccine in goats and change in haematological profile

Levamisole is an anthelmintic and synthetic immunomodulator. Effect of levamisole on PPR vaccine in goat model was evaluated in this study. Healthy, sero negative for PPR infection 12 Black Bengal goats were divided into three groups. Levamisole was injected @ 2.5 mg/kg b.wt. and @ 5.0 mg/kg b.wt. in two groups respectively. After seven days all animals were vaccinated with PPR cell culture vaccine. Blood samples were collected from animals at 0 day, 7th day, 14th day, 21st day and 30th day. Serum was separated and used in indirect ELISA for qualitative and quantitative assay of antibody titer. EDTA mixed blood sample was used for determination of immunity induced blood cells number. Antibody titer and immunity induced blood cells number were more in the Levamisole and vaccine treated groups than only vaccine treated group. So, levamisole acted as an immunomodulator when it was used prior PPR vaccine in goats.

Histopathological study for using of pox inactivated vaccine in goats

This study used goat pox inactivated vaccine (serial No.57,58, year of 2014 ) produced at Biocombinat State Owned Enterprise (SOE).On day 21 and at 1, 3, 6, 9, 12 months after vaccination, the vaccinated animals are challenged with a virulent “Ho” strain by subcutaneous inoculation with 0.1 ml (10-3.5).We have evaluated that the goat pox inactivated vaccine is effective for up to 6 months.Mongolian Journal of Agricultural Sciences Vol.15(2) 2015; 51-55